Systematic review: Can botulinum toxin be recommended as treatment for pain in myofascial syndrome?;Revisión sistemática: ¿es recomendable el empleo de toxina botulínica como tratamiento del dolor en el síndrome miofascial?

Reumatologia Clinica

Volumn 2, Issue 4, 2006, Pages 173-182

  Pereda, Claudia Alejandra ^a   Usón Jaeger, Jacqueline ^b   Carmona, Loreto ^c  

^a Mediterranea Medica Clinic   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c UNIDAD DE INVESTIGACIÓN   (Spain)

Author keywords

Botulinum toxin; Meta analysis; Myofascial syndrome; Systematic review

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BUPIVACAINE; LIDOCAINE; METHYLPREDNISOLONE; PLACEBO; SODIUM CHLORIDE; STEROID;

ANALGESIA; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG COST; DRUG EFFICACY; EMBASE; ERYTHEMA; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; INFECTION; INFORMATION RETRIEVAL; INJECTION SITE REACTION; ISCHIALGIA; LONG TERM CARE; LOW BACK PAIN; MEDLINE; META ANALYSIS; MUSCLE HYPERTONIA; MUSCLE SPASM; MYOFASCIAL PAIN; NECK PAIN; PAIN ASSESSMENT; PARESTHESIA; PHYSIOTHERAPY; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIGGER POINT; VISUAL ANALOG SCALE;

EID: 33748750261     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1699-258X(06)73043-1     Document Type: Article

References (36)

1. Travell JG, Simons DG. Myofascial pain and dysfunction. The trigger point manual. Baltimore: Williams & Wilkins; 1983.
2. De Andrés J, Cerdá-Olmedo G, Valia JC, Monsalve V, López-Alarcón MD, Mínguez A. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain. 2003;19:269-75.
3. Pearce JM. Myofascial pain, fibromyalgia or fibrositis? Eur Neurol. 2004; 52:67-72.
4. Wheeler AH. Myofascial pain disorders: theory to therapy. Drugs. 2004; 64:45-62.
5. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251 Suppl 1:I1-7.
6. Berardelli A, Carta A, Stocchi F, Formica A, Agnoli A, Manfredi M. Botulinum A toxin injection in patients with blepharospasm, torticollis and hemifacial spasm. Ital J Neurol Sci. 1990;11:589-93.
7. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512-5.
8. Durette MR, Rodríguez AA, Agre JC, Silverman JL. Needle electromyographic evaluation of patients with myofascial or fibromyalgic pain. Am J Phys Med Rehabil. 1991;70:154-6.
9. Porta M, Perretti A, Gamba M, Luccarelli G, Fomari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type a. Pain Digest. 1998;8:346-52.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
11. Mahowald ML. Long term of intra-articular botulinum A toxin for re-fractory joint pain. San Antonio: ACR; 2004.
12. Kamanli A, Kaya A, Ozgocmen S, Bayik Y, Ardicoglu O. A comparative study of lidocaine, botulinum toxin type A injection and dry needling in the treatment of myofascial pain syndrome. Lisbon: EULAR Congress; 2003.
13. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005;25:604-11.
14. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59:65-9.
15. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000;85:101-5.
16. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil. 2002;81:751-9.
17. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998; 23:1662-6 [discussion, 1667].
18. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001; 56:1290-3.
19. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain. 2001;94:255-60.
20. Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology. 2003;61:940-4.
21. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology. 1994;80:705-6.
22. Balague F. Injections and low back pain: outcome and randomized controlled trials. Bull Hosp Joint Dis. 1996;55:185-90.
23. Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol. 2000;42:116-21.
24. Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. 2002;205:59-63.
25. Carrasco AT, Wescoat L, Román A. A retrospective review of botulinum toxin type a compared with standard therapy in the treatment of lumbar myofascial back pain patients. Pain Clin. 2003;15:205-11.
26. De Andrés J. New advances in botulinum toxin therapy for pain. Expert Rev Neurotherap. 2002;2:791-9.
27. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000;40:231-6.
28. Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache. 2002;42:1033-7.
29. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712-7.
30. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68: 707-12.
31. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465-73.
32. Paulson GW, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord. 1996;11:459.
33. Porta M. Botulinum toxin type a injections for myofascial pain syndrome and tension-type headache. Eur J Neurol. 1999;6 Suppl 4:S103-9.
34. Porta M. A comparative trial of botulinum toxin type a and methylprednisolone for the treatment of tension-type headache. Pain Digest. 1999;9: 303-6.
35. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache. 2000;40:300-5.
36. Sarifakioglu N, Sarifakioglu E. Evaluating the effects of ice application on the pain felt during botulinum toxin type-a injections: a prospective, randomized, single-blind controlled trial. Ann Plast Surg. 2004; 53:543-6.